Latest News Archive
Please select Category, Year, and then Month to display items
25 March 2024
|
Story Anthony Mthembu
|
Photo Lutendo Mabata
Prof Nompumelelo Zondi, the newly appointed Vice-Dean: Research and Postgraduate Studies in the Faculty of The Humanities at the University of the Free State (UFS).
Prof Nompumelelo Zondi has been appointed as Vice-Dean: Research and Postgraduate Studies in the Faculty of The Humanities at the University of the Free State (UFS). Prof Zondi assumed this new role on 1 March 2024 after serving as the Head of Department for African Languages at the University of Pretoria for seven years. “I consider this appointment as an opportunity of growth and learning more about higher education and the Faculty of The Humanities at large,” she said.
Prof Zondi indicates that part of her role is to spearhead the UFS Vision130 within the Faculty of The Humanities, and to ensure that the faculty assists the institution in becoming research-led, student-centred, and globally impactful.
Motivation for assuming this role
One of the primary reasons that led her to consider this role is sharing the knowledge she acquired as part of the Fulbright South African Research Scholar Programme. As a result of that experience and exposure, which went beyond the Ohio State University, she felt it befitting to implement some of the insights she acquired on a bigger scale. Therefore, even though she was impactful in her previous role, Prof Zondi believes that this is an exceptional and more desirable platform to do so. “I feel that I will have easier access to departments within the faculty, while also encouraging and supporting interdepartmental and faculty collaborations,” she explained.
A significant component of Vision 130
He believes that the elements that make up Vision 130 are interrelated. While she considers research central to Vision 130 – as she begins her journey at the UFS, she feels students deserve to be nurtured to further contribute to the university’s impactful research. Thus, student-centredness is the way to go. “I believe that students must be major role players in this Vision130; we must include them in the interactions and discussions that are part of the university’s strategic plan as well as in decision-making processes,” she said. As such, according to Prof Zondi, the more the faculty and the institution care for the students and involve them in Vision130 and in collaborations, the more research outputs the university will achieve.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004